Literature DB >> 15028127

Idiopathic intracranial hypertension.

Devin K Binder1, Jonathan C Horton, Michael T Lawton, Michael W McDermott.   

Abstract

OBJECTIVE: The history, diagnosis, and therapy of idiopathic intracranial hypertension (IIH) (pseudotumor cerebri) are reviewed. Theories of pathogenesis are considered, the clinical presentation is described, and potential diagnostic and therapeutic challenges are explored.
METHODS: An extensive literature review of IIH and related conditions (secondary pseudotumor syndromes) was performed. The history of and rationale for the diagnosis and medical and surgical approaches to treatment are reviewed. Available outcome studies are presented.
RESULTS: Diagnosis of IIH requires that the modified Dandy criteria be satisfied. Multiple potential contributing causes of intracranial hypertension must be identified or excluded. The clinical presentation most often includes headaches and papilledema, but many other findings have been described. The most important goal of therapy is to prevent or arrest progressive visual loss. Medical therapies include alleviation of associated systemic diseases, discontinuation of contributing medications, provision of carbonic anhydrase inhibitors, and weight loss. Surgical therapies include lumboperitoneal shunting, ventriculoperitoneal shunting, and optic nerve sheath fenestration. On the basis of the advantages and disadvantages of these treatment modalities, a suggested treatment paradigm is presented.
CONCLUSION: Idiopathic intracranial hypertension is the term to be adopted instead of pseudotumor cerebri. IIH remains an enigmatic diagnosis of exclusion. However, prompt diagnosis and thorough evaluation and treatment are crucial for preventing visual loss and improving associated symptoms.

Entities:  

Mesh:

Year:  2004        PMID: 15028127     DOI: 10.1227/01.neu.0000109042.87246.3c

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  54 in total

1.  MR imaging findings in patients with secondary intracranial hypertension.

Authors:  A C Rohr; C Riedel; M-C Fruehauf; A van Baalen; T Bartsch; J Hedderich; K Alfke; L Doerner; O Jansen
Journal:  AJNR Am J Neuroradiol       Date:  2011-04-21       Impact factor: 3.825

2.  Quantitative evaluation of papilledema from stereoscopic color fundus photographs.

Authors:  Li Tang; Randy H Kardon; Jui-Kai Wang; Mona K Garvin; Kyungmoo Lee; Michael D Abràmoff
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-03       Impact factor: 4.799

3.  Lumboperitoneal shunt for idiopathic intracranial hypertension: patients' selection and outcome.

Authors:  Waleed F El-Saadany; Ahmed Farhoud; Ihab Zidan
Journal:  Neurosurg Rev       Date:  2011-09-29       Impact factor: 3.042

Review 4.  Pseudotumor cerebri.

Authors:  Pietro Spennato; Claudio Ruggiero; Raffaele Stefano Parlato; Maria Consiglio Buonocore; Antonio Varone; Emilio Cianciulli; Giuseppe Cinalli
Journal:  Childs Nerv Syst       Date:  2010-08-19       Impact factor: 1.475

5.  Idiopathic intracranial hypertension is not benign: a long-term outcome study.

Authors:  Hanne M Yri; Marianne Wegener; Birgit Sander; Rigmor Jensen
Journal:  J Neurol       Date:  2011-10-19       Impact factor: 4.849

6.  Improvement in venous outflow following superior sagittal sinus decompression after a gunshot wound to the head: case report.

Authors:  Daniel M Birk; Matthew K Tobin; Heather E Moss; Eric Feinstein; Fady T Charbel; Ali Alaraj
Journal:  J Neurosurg       Date:  2015-04-03       Impact factor: 5.115

7.  Response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia.

Authors:  Charles J Glueck; Karl C Golnik; Dawit Aregawi; Naila Goldenberg; Luann Sieve; Ping Wang
Journal:  MedGenMed       Date:  2005-11-10

8.  Reversibility of venous sinus obstruction in idiopathic intracranial hypertension.

Authors:  A Rohr; L Dörner; R Stingele; R Buhl; K Alfke; O Jansen
Journal:  AJNR Am J Neuroradiol       Date:  2007-04       Impact factor: 3.825

9.  Macular thickness measurements with frequency domain-OCT for quantification of axonal loss in chronic papilledema from pseudotumor cerebri syndrome.

Authors:  M L R Monteiro; C L Afonso
Journal:  Eye (Lond)       Date:  2014-01-10       Impact factor: 3.775

10.  Acetazolamide for pseudotumor cerebri: evidence from the NORDIC trial.

Authors:  Jonathan C Horton
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.